Schott Pharma stock gains as Xetra price moves higher

Published on 09/01/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Schott Pharma stock is trading higher on Xetra, with investors looking at recent price dynamics and the latest reported figures for the drug-delivery specialist.

Schott Pharma, DE000A3ENQ51, Illustration mit AI erstellt.

Schott Pharma (ISIN DE000A3ENQ51) stock was quoted at 23.30 EUR on the Düsseldorf exchange on September 1, 2026, implying a gain of 3.10% versus the previous close according to data for SCHOTT Pharma AG & Co. KGaA published by Börse Düsseldorf at 16:30 local time on that day. For Xetra trading, market data compiled by finanzen.ch show intraday moves between 23.20 EUR and 23.55 EUR on September 1, 2026, indicating steady buying interest around the mid-20-euro range.

Stock moves within intraday range

According to morning Xetra data compiled by finanzen.ch, Schott Pharma opened at 23.20 EUR on September 1, 2026 and traded up 0.2% to 23.20 EUR at 09:28, with a session high of 23.35 EUR at that stage. A subsequent update from the same source at 12:28 reported the share at 23.40 EUR, up 1.1% on the day, with a then intraday high of 23.55 EUR. In parallel, the Düsseldorf quote table shows Schott Pharma at 23.30 EUR at 16:30 on September 1, 2026, corresponding to a 3.10% advance and underscoring that the stock remained near the upper end of its intraday range by the late afternoon on a German trading venue that is relevant for DACH investors.

Analyst views and upside to targets

A recent overview of analyst opinions on Schott Pharma published by finanzen.ch in August 2026 highlights that, at that time, the average analyst price target stood 0.96 EUR above the then current Xetra price. With the cited Xetra level at 23.15 EUR during that August review, this implies a consensus target of approximately 24.11 EUR, signaling about 4.1% upside potential relative to that specific price snapshot. For investors, this moderate gap between market price and average target underscores a cautiously positive stance among covering analysts, although the exact number of houses and ratings behind that average is not detailed in the summary.

Go deeper

More Schott Pharma stock coverage

Further real-time news and regulatory disclosures for Schott Pharma can be found in the dedicated ISIN overview.

All news on DE000A3ENQ51 Investor Relations

Drug delivery solutions as core business

Schott Pharma focuses on advanced container systems and components for injectable drugs, building on its parent group’s long-standing expertise in specialty glass and polymer solutions for pharmaceutical applications. Industry analyses such as a syringe tip covers market outlook by IndexBox list Schott AG among key manufacturers of glass-based syringe tip covers, illustrating the broader ecosystem in which Schott Pharma’s containers and drug-device interfaces are deployed alongside other components used by biopharma customers. For revenue, profitability and segment data, investors increasingly look to the company’s investor-relations disclosures and half-year reports, which detail performance in areas such as prefillable syringes and vials, but the most recent interim figures are not explicitly broken out in the same-day news snippets inspected here.

Schott Pharma stock for DACH investors

Schott Pharma stock is traded on Xetra and other German venues, with the Düsseldorf exchange order book on September 1, 2026 showing a 23.30 EUR quote at 16:30, a bid size of 430 shares at 23.30 EUR and an ask at 23.40 EUR for the same volume. For retail investors in the DACH region, these data points give a snapshot of liquidity and the narrow spread in the stock at that time, complementing Xetra’s intraday range from 23.20 EUR to 23.55 EUR as reported by finanzen.ch. While broader European equity indices such as the STOXX 600 were only marginally positive on September 1, 2026, with a 0.04% gain according to a European market update, Schott Pharma’s move of around 1.1% intraday on Xetra and 3.10% on Düsseldorf suggests that the stock was modestly outperforming the regional benchmark on that date.